736 results about "Active compound" patented technology

The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to TNF-like ligand 1A (TL1A). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing same, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof according to the invention, as well as to pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof according to the invention and other therapeutically active compounds; to methods for treating TL1A-mediated diseases or disorders, to use of the antibody or antigen-binding fragment thereof or pharmaceutical composition thereof for treating TL1A-mediated diseases or disorders, and to use of the antibody or antigen-binding fragment thereof according to the invention and other therapeutically active compounds for treating TL1A-mediated diseases or disorders.

The present invention relates to novel lignin-derived compounds and compositions comprising the same and their use as redox flow battery electrolytes. The invention further provides a method for preparing said compounds and compositions as well as a redox flow battery comprising said compounds and compositions. Additionally, an assembly for carrying out the inventive method is provided.

Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I):or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L, L1, L2, L3, L4, M, q, w and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.

The present invention relates to fungicidal mixtures comprising at least one substituted pyridine (compound I) and at least one active compound II in a weight ratio of from 100: 1 to 1: 100; to a method for controlling phytopathogenic harmful fungi using a mixture of at least one compound I and at least one compound II in a weight ratio of 100: 1 to 1: 100; to the use of a mixture comprising compound I and compound II for controlling phytopathogenic harmful fungi; to agrochemical compositions comprising these mixtures; and to agrochemical compositions further comprising seeds.

The invention relates to the technical field of substance detection and analysis, in particular to a method for identifying lactone odor active compounds in milk. According to the method for identifying the lactone odor active compounds in the milk, provided by the invention, the pretreatment of the milk sample is performed by combining the thin-film solid-phase microextraction with the sequential stirring rod adsorption method, and the gas chromatography-sniffing-mass spectrometry technology is matched, so that the sniffing detection rate of the lactone odor active compounds in the milk is remarkably increased; the method has the advantages of high efficiency, strong operability, environmental protection and the like, and has important application value in milk lactone odor active compound detection and milk flavor evaluation.

The present invention relates to fungicidal mixtures comprising at least one substituted pyridine (compound I) and at least one active compound II in a weight ratio of from 100: 1 to 1: 100; to a method for controlling phytopathogenic harmful fungi using a mixture of at least one compound I and at least one compound II in a weight ratio of 100: 1 to 1: 100; to the use of a mixture comprising compound I and compound II for controlling phytopathogenic harmful fungi; to agrochemical compositions comprising these mixtures; and to agrochemical compositions further comprising seeds.

Disclosed are novel pharmaceutical, animal feed compositions and methods of treating non-human animals comprising at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s), or mixtures thereof, derived from non-woody plants of the genus Hesperaloe. Animal feed compositions may comprise a basal animal feed and water soluble solids extracted from Hesperaloe and comprising at least one saponin. The water soluble solids may comprise from about 5 to about 30 wt % saponin. The compositions of the present invention can be used for the treatment of non-human animals, such as poultry and more particularly for preventing and treating coccidiosis. An embodiment provides an immunological composition useful for inducing the production of antibodies to an antigen in a non-human animal comprising an antigen, preferably a coccidia, and a saponin composition extracted from Hesperaloe. The saponins extracted from Hesperaloe biomass may comprise 25(27)-dehydrofucreastatin, 5(6),25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin and yuccaloiside C.

The invention discloses a virtual drug screening method and system based on adaptation during testing. The method comprises the following steps that a historical data set of protein pocket-small molecule pairing is collected; constructing a double-encoder framework consisting of a protein pocket encoder and a small molecule encoder; performing joint training on the double-encoder architecture based on the historical data set to obtain a small molecule screening model; and obtaining protein pocket data, and screening and sequencing the candidate small molecules corresponding to the protein pocket data based on the small molecule screening model to obtain corresponding active compounds. According to the method, the adaptation technology during testing is introduced into the virtual drug screening task for the first time, structural specificity dynamic adaptation of the model to an unknown sample is achieved on the premise of not depending on a test label, and the generalization performance is remarkably improved.

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

The invention discloses marine-derived penicillium as well as a fermentation method and application thereof. The marine source penicillium is named as Penicillium sp.DSF059, and the preservation number of the marine source penicillium is CCTCC (China Center For Type Culture Collection) NO: M 20232310. According to the invention, the culture conditions of the strain are optimized, the culture medium and culture conditions with high yield of antibacterial active compounds are selected for fermentation, more target products can be obtained, the operation is simple, the cost is low, and the method is suitable for industrial production. Meanwhile, the marine-derived penicillium sp. DSF059 can provide an excellent strain for the development of new drugs for resisting plant pathogens such as coffee leaf blight, coffee brown spot, grape gray mold, golden cypress brown spot, citrus black rot, phytophthora capsici, hickory leaf blight and coffee black spot as well as four pathogens separated from coffee leaf diseases and staphylococcus aureus; good application prospects are realized on prevention and treatment of phytopathogen and staphylococcus aureus.

The invention is directed to a biodegradable, thermoplastic multiblock copolymer, to a process for preparing a biodegradable, thermoplastic multiblock copolymer, to the use of a biodegradable thermoplastic multiblock copolymer, to a composition for the delivery of at least one pharmacologically active compound to a host, and a medical device comprising a biodegradable, thermoplastic multiblock copolymer. The biodegradable, thermoplastic multiblock copolymers of the invention comprise at least one prepolymer (A) segment and at least one hydrolysable amorphous prepolymer (B) segment, wherein the segments are linked by a multifunctional chain extender, wherein the at least one prepolymer (A) segment comprises: a) one or more hydrolysable linkages, b) a water-soluble polyoxazoline-based polymer, and c) reaction products of one or more cyclic monomers and / or one or more non-cyclic monomers, wherein the water-soluble polyoxazoline-based polymer is a polymer containing a repeating unit of structure −[N(COR1)CH2CH2]n− where R1 is independently selected for each repeating unit from an alkyl group and n is 3-100, and wherein the multiblock copolymer is amorphous.

The invention relates to the field of demulsifiers, in particular to an oil sludge demulsifier as well as a preparation method and application thereof. The oil sludge demulsifier comprises the following components in parts by mass: 20-35 parts of a surface active compound, 7-12 parts of a sodium alkyl sulfate cosolvent, 0.6-1.8 parts of a stabilizer and 48-55 parts of water, wherein the surface active compound comprises hyperbranched polyamidoamine and polyether amine modified magnetic nanoparticles. According to the oil sludge demulsifier, the problems that most of existing demulsifiers are small in dehydration amount, low in dehydration speed, poor in demulsification effect and low in treated oil content are solved, the demulsification performance of the oil sludge demulsifier is improved, the demulsification and dehydration efficiency is improved, and effective separation of oil sludge is achieved.

The present invention relates to a group of cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof. The cannabinoid derivatives of the invention are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivatives of the invention

The invention belongs to the technical field of pesticide preparations, and relates to a preparation method and application of prothioconazole sustained-release microspheres. The preparation method comprises the following steps: adding an active compound, an emulsifier, isocyanate and polycaprolactone polyol into cyclohexanone, and uniformly mixing to obtain an oil phase; adding a dispersing agent into water and uniformly mixing to obtain a water phase; and adding dibutyltin dilaurate into the oil phase, reacting, mixing with the water phase, shearing, and stirring to obtain the prothioconazole sustained-release microsphere suspending agent. The prothioconazole sustained-release microsphere prepared by the process still keeps higher bactericidal activity on the premise of good leaf surface stability, so that reduction of the pesticide application frequency, improvement of the pesticide utilization rate and long-acting prevention and control of prothioconazole in the field are expected to be realized, and the prothioconazole sustained-release microsphere conforms to the national double reduction policy and is suitable for large-scale popularization and application.

The invention discloses application of an active compound in an anti-cataract drug, and particularly relates to the field of drugs. The active compound is lenalidomide, mycophenolic acid, glycyrrhetinic acid or bromfenac sodium hydrate. Through a solution based on a CRYAB structure and animal experiment screening, it is found that the active compound can serve as an effective component of an anti-cataract drug, the progress of cataract can be remarkably relieved or inhibited, and a new strategy and potential drug selection are provided for treatment of cataract.

The present disclosure is generally directed to an agricultural formulation comprising an anucleated minicells and an anucleated cell-based platforms for encapsulation and scalable delivery of biologically active compounds. Disclosed herein are compositions for the stable and targeted delivery of biologically active compounds within achromosomal and / or anucleated cells onto and / or into a target cell. The present disclosure also provides methods of improving encapsulation and retention of biologically active compounds in achromosomal and / or anucleated cells and delivering biologically active compounds into a target cell.

The present invention relates to isoxazoline compounds of formula I, wherein the variables have the meanings as defined in the description; to a composition comprising the same; to active compound combinations comprising the same; and to the use thereof for protecting growing plants and animals from infestation or infestation by invertebrate pests; furthermore, to seeds comprising such compounds. Preferred compounds are, for example, N-(3-(aminomethyl)-4-fluorophenyl)-5-(4-fluorophenyl)-5-(trifluoromethyl)-4, 5-dihydroisoxazole-3-amine derivatives. # imgabs0 #

The present invention relates to novel active compound combinations comprising the compound of the formula (I) and at least one further active compound of the group (II) which combinations are highly suitable for controlling animal and microbial pests.

The invention belongs to the technical field of chemical pharmacy, and particularly relates to a preparation method and application of an impurity of a beta2 adrenal receptor stimulant and M receptor antagonist bifunctional active compound. According to the impurity preparation method of the beta2 adrenal receptor stimulant and M receptor antagonist bifunctional active compound, acetylation of amino is successfully realized by using acetylation reagents such as acetyl chloride and alkali accelerators such as N, N-diisopropylethylamine, then debenzylation is performed through hydrogenation reaction, and the compound shown in the formula I is successfully prepared. Then, through liquid chromatography purification, a high-purity compound as shown in the formula I is obtained, and the raw material medicine as shown in JKN2304 can meet the requirements of reference substances in the research and development process; the technical problem that in the prior art, an impurity synthesis process of a beta 2 adrenal gland receptor agonist and M receptor antagonist bifunctional active compound is lacked is solved.

The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to thymic stromal lymphopoietin (TSLP). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing same, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody according to the invention, pharmaceutical compositions comprising the antibody according to the invention and other therapeutically active compounds, methods for treating diseases or disorders mediated by thymic stromal lymphopoietin (TSLP), uses of the antibodies or pharmaceutical compositions thereof for treating diseases or disorders mediated by TSLP, and uses of the antibodies and other therapeutically active compounds for treating diseases or disorders mediated by TSLP.

The invention provides a preparation method and application of a nicosulfuron Ia crystal form, and the preparation method comprises the following steps: mixing and stirring a nicosulfuron raw material and an alcoholic solution, and then cooling and filtering to obtain the nicosulfuron Ia crystal form, the nicosulfuron raw material is a product prepared from nicosulfuron or a nicosulfuron active compound. According to the preparation method provided by the invention, the crystal form conversion time is remarkably shortened, the purpose of rapidly preparing the stable crystal form of the nicosulfuron is achieved, additional equipment and facilities do not need to be added, only an original crystallization device needs to be used, the production cost is controlled, and the preparation method is suitable for industrial production.

Methods of making bioactive compound-loaded nanoparticles are provided. The methods harness naturally-occurring biopolymers to produce nanoparticles from raw plant materials. Methods include contacting plant-derived materials with alkaline solution with agitation to deprotonate the bioactive materials and biopolymers to form nanoparticles. In some forms, the methods contact the nanoparticle with an acid to re-protonate the components and more stable nanoparticles. The bioactive compounds can be extracted from raw plants and / or plant parts, including turmeric, ginger, clove, thyme, pepper, and rosemary. The bioactive compounds include curcumin, gingerols, shogaols, eugenol, thymol, carvacrol, capsaicin, and rosmarinic acid. Compositions and formulations containing bioactive-compound loaded nanoparticles are also provided.

Moulding material mixture of natural and / or ceramic sands with a phenol-formaldehyde resin-free binder for foundry moulding sands, wherein the binder is either ➢as a one-component binder based on polyurethane and / or polyurea, comprising an aromatic or aliphatic oligomeric and / or polymeric isocyanate or a mixture of several aromatic and / or aliphatic oligomeric and / or polymeric isocyanates with partially delayed reactivity, and as an additive a non-functional diluent, wherein the isocyanates consist entirely or partially of pre-crosslinked reaction products, and wherein the pre-crosslinking is brought about by the reaction with di- or polyfunctional polyols with a stoichiometric deficit of hydrogen-active compounds, resulting in a residual content of free isocyanate groups in the range of 5 to 35%, and wherein the one-component binder is suitable for a multi-phase curing process using water-alcohol mixtures, or ➢ as a two-component binder based on polyurethane and / or polyurea, comprising . a component A with an average hydrogen functionality of 2.0 to 3.9, with an average equivalent weight of 450 to 900 g / eq of the reactants and with functional and / or non-functional additives that control the reactivity, non-functional admixtures that promote processability and ensure stability, wherein the reactants of component A are polyether alcohol mixtures of hydroxyl and / or mercapto groups and / or internal nitrogen-containing individual components, wherein the hydrogen-active compounds of the mixture of component A • two- to eight-functional polyether alcohols obtained by anionic or cationic ring-opening polymerization of cyclic ethers and simultaneous addition of the resulting polyether chains to OH / NH starter molecules and / or • Polythiols resulting from the esterification reaction of 3-mercaptopropionic acid with two or more alcohols or which are hydrogen-active polysulfide polymers with free SH groups, are selected and combined, and • an isocyanate-containing component B is present.

The present disclosure features methods for identifying pateints having a hyperproliferative disease, disorder, or condition responsive to phosphodiesterase 3 (PDE3) and schlafen family member 12 (SLFN12) complex formation. The hyperproliferative disease, disorder, or condition may be cancer in a patient including glioblastoma, melanoma, ovarian cancer, cervical cancer, sarcoma, or hematopoietic cancers, such as acute myeloid leukemia. Those responsive diseases, disorders, or conditions may be identified using the biomarker AIP and / or TRRAP in combination with those biomarkers pertinent to phosphodieseterase 3 and schlafen family member 12 complexes which may be formed by PDE3 modulation with certain active compounds. Expression of combinations of these biomarkers have been shown to correlate with active compound (e.g., PDE3 modulator, PDE3A modulator, PDE3B modulator) sensitivity.

According to the AI-assisted marine microorganism anti-tumor activity product separation method provided by the invention, a microorganism strain with high anti-tumor activity potential can be directly and quickly screened out by constructing a marine microorganism sample database and applying a trained HetGNN model; the workload and time cost of tedious fermentation culture and biological activity testing in a traditional screening process are greatly reduced, meanwhile, the screening period is shortened, and the screening efficiency is greatly improved. Besides, a closed-loop feedback system formed by the invention feeds back a high-purity target compound sample separated from a laboratory and related data thereof to a microorganism sample database, and continuously optimizes the integrity of the database and the performance of the HetGNN model, so that the accuracy and efficiency of subsequent anti-tumor active compound screening are remarkably improved; the problem that in the prior art, screening precision is limited by initial data, and iterative upgrading is difficult is solved.

An oral product includes a filler and an active ingredient. The filler includes a modified agglomerate and a surface modifier. The modified agglomerate includes a porous carrier. The surface modifier coats at least a portion of a surface of the agglomerate, is in pores of the agglomerate, or both coats at least a portion of the surface of the agglomerate and is in pores of the agglomerate. The surface modifier includes a sugar alcohol or a hydrophobic material. The active ingredient is admixed with the filler.

The present invention relates to a method and apparatus for predicting the effect of the co-administration of a secondary active compound on the bioavailability of a primary active compound.

A pouch 200 for transmucosal delivery of a neuroactive, psychoactive and / or bioactive compound in the mouth of a human or animal subject, comprises a liquid permeable cover 202 and a plurality of dissolvable lozenges 204, 206, 208 contained within the cover. Each of the plurality of lozenges comprises a matrix material and a neuroactive, psychoactive and / or bioactive compound suspended within the matrix material. A first lozenge of the plurality of lozenges comprises a first matrix material and a first concentration of a neuroactive, psychoactive and / or bioactive compound suspended in the first matrix for delivering a first dosage profile to the human or animal subject. A second lozenge of the plurality of lozenges comprises a second matrix material and a second concentration of the and / or a further neuroactive, psychoactive and / or bioactive compound suspended in the second matrix for delivering a second dosage profile to the human or animal subject. The pouch may also include an inner permeable cover (304, fig 3), which includes a plurality of inner dissolvable lozenges (308, fig 3). A first lozenge may comprise a plurality of layers (402, 404, fig 4), for delivering a different concentration and / or a further neuroactive, psychoactive and / or bioactive compound.

The invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody specifically bound with AXL or an antigen binding fragment of the monoclonal antibody. The invention also relates to nucleic acids encoding said antibodies, expression vectors, host cells and methods of producing the same, methods of producing the antibodies according to the invention, pharmaceutical compositions comprising the antibodies according to the invention, pharmaceutical compositions comprising the antibodies according to the invention and other therapeutically active compounds, methods of treating AXL-mediated diseases or disorders, and methods of treating AXL-mediated diseases or disorders. The use of the antibodies or pharmaceutical compositions thereof for the treatment of AXL-mediated diseases or disorders and the use of the antibodies and other therapeutically active compounds for the treatment of AXL-mediated diseases or disorders.

The invention provides an insecticidal suspending agent composition compounded from diafenthiuron and dinotefuran, and the problem of generation overlapping of target insects can be solved by utilizing the ovicidal effect of diafenthiuron and the characteristic that dinotefuran has a special effect on piercing-sucking mouthpart pests. A three-stage grinding process is adopted in the production process, so that raw medicine particles can be finer, and the raw medicine particles can penetrate through air holes more easily to reach a target body; the synergistic additive is added after grinding and before subpackaging, so that the stability of the preparation can be improved, the plant-source synergistic additive is prevented from being decomposed, and the production cost is saved. The botanical synergistic auxiliary agent can greatly reduce the surface tension of a diluent, draw active compound particles, penetrate through a plant wax coat to directly reach a target to play a role, and can also prolong the adhesion time of a liquid medicine on the surface of a plant through a coating effect, delay the degradation of an active compound, prolong the lasting period and reduce the pesticide application frequency.